Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, National Health Insurance Service Medical Center, Ilsan Hospital, Goyang, Republic of Korea.
Atherosclerosis. 2024 Aug;395:117563. doi: 10.1016/j.atherosclerosis.2024.117563. Epub 2024 Apr 23.
High coronary artery calcification (CAC) burden is a significant risk factor for adverse cardiovascular and kidney outcomes. However, it is unknown whether changes in the coronary atherosclerotic burden can accompany changes in kidney disease progression. Here, we evaluated the relationship between CAC progression and the risk of kidney failure with replacement therapy (KFRT).
We analyzed 1173 participants with chronic kidney disease (CKD) G1 to G5 without kidney replacement therapy from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Participants were categorized into three groups according to the change in the CAC score between enrollment and year 4 (non-progressors, ≤0 AU; moderate progressors, 1-199 AU; and severe progressors, ≥200 AU). The primary outcome was the development of KFRT.
During a follow-up period of 4690 person-years (median, 4.2 years), the primary outcome occurred in 230 (19.6 %) participants. The incidence of KFRT was 37.6, 54.3, and 80.9 per 1000 person-years in the non-, moderate, and severe progressors, respectively. In the multivariable cause-specific hazard model, the hazard ratios (HRs) for the moderate and severe progressors were 1.71 (95 % confidence interval [CI], 1.02-2.87) and 2.55 (95 % CI, 1.07-6.06), respectively, compared with non-progressors. A different definition of CAC progression with a threshold of 100 AU yielded similar results in a sensitivity analysis.
CAC progression is associated with an increased risk of KFRT in patients with CKD. Our findings suggest that coronary atherosclerosis changes increase the risk of CKD progression.
高冠状动脉钙化(CAC)负担是心血管和肾脏不良结局的重要危险因素。然而,尚不清楚冠状动脉粥样硬化负担的变化是否伴随着肾脏疾病进展的变化。在这里,我们评估了 CAC 进展与需要肾脏替代治疗的肾衰竭(KFRT)风险之间的关系。
我们分析了来自韩国慢性肾脏病患者结局的队列研究(KNOW-CKD)的 1173 名无肾脏替代治疗的慢性肾脏病(CKD)G1 至 G5 患者。根据 CAC 评分在入组时和第 4 年之间的变化,将参与者分为三组(非进展者,≤0 AU;中度进展者,1-199 AU;严重进展者,≥200 AU)。主要结局是 KFRT 的发生。
在 4690 人年的随访期间(中位数为 4.2 年),230 名(19.6%)参与者发生了主要结局。非进展者、中度进展者和严重进展者的 KFRT 发生率分别为每 1000 人年 37.6、54.3 和 80.9 例。在多变量原因特异性风险模型中,与非进展者相比,中度和严重进展者的风险比(HR)分别为 1.71(95%置信区间 [CI],1.02-2.87)和 2.55(95% CI,1.07-6.06)。在敏感性分析中,使用 CAC 进展阈值为 100 AU 的不同 CAC 进展定义也得到了类似的结果。
在 CKD 患者中,CAC 进展与 KFRT 风险增加相关。我们的研究结果表明,冠状动脉粥样硬化变化增加了 CKD 进展的风险。